EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer

Liza C Villaruz iD, George R Blumenschein, Gregory A Otterson, Ticiana A Leal

Cancer · 2023

DOI: 10.1002/cncr.34683 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2023. Verfasst von Liza C Villaruz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The availability of agents targeting the programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) immune checkpoint has transformed treatment of advanced and/or metastatic non–small cell lung cancer (NSCLC). However, a substantial proportion of patients treated with these agents do not respond or experience only a brief period of clinical benefit. Even among those whose disease responds, many subsequently experience disease progression. Consequently, novel approaches are needed that enhance antitumor immunity and counter resistance to PD‐(L)1 inhibitors, thereby improving and/or prolonging responses and patient outcomes, in both PD‐(L)1 inhibitor‐sensitive and inhibitor‐resistant NSCLC. Mechanisms contributing to sensitivity and/or resistance to PD‐(L)1 inhibitors in NSCLC include upregulation of other immune checkpoints and/or the presence of an immunosuppressive tumor microenvironment, which represent potential targets for new therapies. This review explores novel therapeutic regimens under investigation for enhancing responses to PD‐(L)1 inhibitors and countering resistance, and summarizes the latest clinical evidence in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorImmunotherapyB7-H1 AntigenTumor Microenvironment

Stichwörter der Autor:innen

drug resistanceimmunotherapyneoplasmnon-small cell lung cancerprogrammed cell death protein 1programmed death-ligand 1tumor escape

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • The Ohio State University-James Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Liza C Villaruz

Förderung

  • NCI NIH HHS

Zitieren

APA

Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. (2023). Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.34683

Vancouver

Villaruz LC, Blumenschein GR, Otterson GA, Leal TA. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer. Cancer. 2023. doi:10.1002/cncr.34683

BibTeX
@article{Villaruz2023,
  author = {Villaruz, Liza C and Blumenschein, George R and Otterson, Gregory A and Leal, Ticiana A},
  title = {Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34683}
}
Kostenlos starten →